GLA gene therapy (Takeda/GentiBio)

N/A

Report date: 2025/01/26 15:41:30

Base Information

Drug NameGLA gene therapy (Takeda/GentiBio)
Drug Alias Namerecombinant AAV vector-based GLA gene therapy (Takeda/GentiBio)
ClassificationBiologics
Mechanisms of Actionα-Galactosidase stimulants
Targetsα-Galactosidase
Therapy Area/IndicationsFabry Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGentiBio IncTakeda Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsFabry Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A